- Rating
- 2
- Confidence
- 2
- Informativeness
- 2
- Presentation
- 2
- Soundness
- 1
Read review
Paper summary
This paper proposes OGPCMIL for few-shot whole-slide image (WSI) subtyping of rare cancers using histopathology and transcriptomic data. The method introduces omics-guided low-rank prototype calibration and class-conditional attention aggregation to address overfitting in multimodal fusion and global–local misalignment. Experiments are conducted on three TCGA cohorts under different few-shot settings and pathology foundation models, with additional ablation and sensitivity analyses.
Critical strengths
-
The paper identifies relevant challenges in few-shot multimodal pathology and presents a reasonably coherent framework. The low-rank calibration strategy provides a constrained mechanism for incorporating genomic information.
-
The evaluation covers multiple datasets, few-shot settings, and pretrained backbones, with several ablation and sensitivity analyses.
Critical weaknesses
1 The main claim of outperforming baselines in 18 of 27 settings relies on win counts, while many performance differences are small relative to the reported variability. No paired statistical significance tests are provided. Moreover, the proposed method underperforms several baselines in certain settings, raising concerns about its robustness and generalizability.
-
Despite focusing on multimodal learning, the paper lacks comparisons with established omics-aware or multimodal fusion methods. Consequently, the claimed advantages over conventional cross-modal fusion remain unverified. Additionally, key ablations are restricted to a single favorable dataset–backbone configuration, making it difficult to assess whether the proposed components consistently contribute across different settings.
-
The pathway analysis relies on gradient-based attribution without sufficient validation, while the localization results lack quantitative comparisons or expert assessment. The calibration analysis is also limited to a single configuration. These results do not adequately establish that the omics-guided mechanism provides clinically meaningful or biologically reliable explanations.
-
The trainable parameter counts of the proposed method and baselines are not reported, making it difficult to assess whether improvements arise from the proposed design or differences in model capacity. Some notation and terminology also require clarification.
Questions for authors
- Why are established omics-aware or multimodal MIL baselines excluded, given that multimodal fusion is central to the paper's contribution?
- Can the key ablation experiments be extended to additional datasets and foundation models to demonstrate consistent effectiveness?